# Contact pureformpeptide — Editorial Desk

> Reach the pureformpeptide editorial desk regarding citations, corrections, or research-related correspondence about our growth-hormone axis and longevity research digest.

Correspondence on citations, corrections, and research-related inquiries about the GH-axis and longevity literature — the things a reference desk most needs to hear.

## Editorial correspondence

pureformpeptide welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory reference that has gone out of date, or a peer-reviewed study on NAD+, Ipamorelin, CJC-1295, or MOTS-c that should be added to the [references page](/references). Notes that identify a specific passage and include a DOI or PubMed ID for the proposed correction are the most useful messages we receive and will be read carefully.

**Editorial mailbox:** editorial@pureformpeptide.com

## What this desk cannot do

pureformpeptide is a literature digest, not a clinic and not a vendor, so several categories of inquiry fall outside what this site can address:

- Advise on, recommend, or comment on human use of any compound discussed here.
- Suggest a dose, schedule, or route of administration for any individual — including questions about dosing protocols that appear in online communities.
- Diagnose a condition or evaluate whether a research finding applies to a particular person's situation.
- Sell, source, identify, recommend, or help locate any compound from any supplier.
- Respond to athlete anti-doping queries about Ipamorelin, CJC-1295, or MOTS-c, given that all three are prohibited substances in competitive sport.

Readers seeking guidance on any health matter should consult a licensed clinician in their own jurisdiction. Editorial correspondence is not guaranteed a reply and may be delayed; the mailbox is monitored intermittently.

---

An independent literature desk for the growth-hormone axis and longevity research — what the peer-reviewed record actually shows, stated plainly and cited precisely.